General information, not legal or regulatory advice. Confirm current agency, holder, import, and post-market rules with qualified advisers. We do not invent Pure Global, freelancer, or competitor rates. Where a card is mentioned, only the locked public LATAM Launch Subscription (USD 7,500/year all-in for the first device family) already published on market-access and the holder hub applies. No unpublished client. No PHI. Always bioaccess®.
If you searched Dominican Republic RA consultant, regulatory affairs consultant medical device Dominican Republic, or MINSA Dominican Republic medical device RA, you were shopping an operator problem under a consultant label. Sponsors sometimes type “RA consultant” when they mean first-in-human (FIH) / early feasibility start-up in the Dominican Republic — ethics calendar, investigational import, site network, and inspection-ready ops — not a freelance classification memo. This page owns that search intent. It does not name freelancers. No PHI. Always bioaccess®.
The leak: a consultant who drafts dossiers, advises on classification, or emails a ministry contact is still not the ethics calendar + importer of record (IOR) + site network + inspection-ready operations stack. Advice is not execution. bioaccess® is the LATAM FIH CRO and local RA / IOR operator that owns that stack — not a LinkedIn RA title with a PDF retainer.
What the search usually means vs what execution requires
- Search intent often means: “Who can get my device through Dominican Republic regulatory / ethics / import so I can run FIH or early feasibility?” — typed as “RA consultant” instead of “CRO” or “IOR.”
- Execution requires: accredited ethics calendar; national / ministry pathway as applicable (MINSA-DR / related device and research files on live bioaccess® Dominican Republic and Caribbean pages); investigational or commercial import entity on the entry; trained sites and investigators; ISO 14155-aligned monitoring and TMF discipline; inspection-ready ISF.
- A freelance RA retainer usually covers: classification opinion, dossier outline, translation coordination, agency Q&A coaching — valuable, and still not the operator stack above.
- You still need: who sits ethics, who is on the import entry, who owns the site contracts, who owns monitoring and CAPA when the inspector asks.
Dominican Republic FIH shopped as “RA consultant”
Caribbean and Dominican Republic FIH searches often collapse into “find me an RA person who knows MINSA.” That is how FIH / registration work leaks away from operators. bioaccess® treats Dominican Republic as part of the LATAM / Caribbean FIH and market-access footprint described on market-access and country / blog pathways already live on bioaccessla.com — not as a freelance inbox. We will not invent a MINSA-DR statutory clock on this page. Confirm current ethics and ministry calendars with qualified advisers and the live Dominican Republic / Panama / Caribbean pages you already publish from, rather than treating a Google snippet as start-up.
Investigational import is a different workstream from commercial holder / IOR. See importer of record for clinical trial devices in Latin America. Commercial already-cleared devices sit on the holder line: LATAM Registration Holder and IOR. Do not put FIH import and commercial registro on one Gantt labeled “Dominican Republic RA.”
Operator stack bioaccess® still owns after an RA quote
- Ethics calendar ownership — committee submission packages, responses, and a real date for first possible enrollment — not a slide that says “ethics TBD.”
- IOR / import entity — who appears on the customs entry for investigational or commercial product; see the live IOR blog above. A consultant who “helps appoint” is not the entity on the entry.
- Site network and contracts — investigators, hospital agreements, budgets, and start-up that survive audit. A hallway introduction is not a site.
- Inspection-ready ops — ISO 14155 monitoring, TMF/ISF discipline, CAPA. Dossier advice does not replace that.
- Registration holder where the SKU is commercial — own-entity holder / IOR under the locked public LATAM Launch Subscription card (USD 7,500/year all-in for the first device family) already published on market-access and the holder hub. We do not invent freelancer rates for comparison.
Colombia line (cluster hygiene)
Public line, unchanged: Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. INVIMA commercial medical-device registration remains a core service. Always bioaccess®. Dominican Republic FIH shopping does not reopen Colombia FIH. Country 2 options stay Panama, Chile, Brazil, Mexico, or El Salvador on the public FIH line — not a new Colombian CTA from this page.
Frequently asked questions
Is an RA consultant a CRO?
No. A regulatory-affairs consultant advises on classification, dossiers, and agency process. A CRO runs protocol execution: ethics, sites, monitoring, data, and inspection readiness. bioaccess® is both the LATAM FIH CRO and the local RA / IOR operator when the SKU requires holder or import — that is the stack gap this search usually hides.
Does bioaccess® replace freelancers?
bioaccess® does not attack named freelancers on this page. We own the search intent: when the job is FIH start-up, registration holder, or IOR, hire the operator that holds the calendar, the entity, and the sites — not only a dossier coach. Sponsors may still use specialist RA advice inside a larger program; that advice is not a substitute for the stack.
Can I run Dominican Republic FIH with “just an RA consultant”?
Not if you mean first patient in under an inspection-ready file. You still need ethics, import, sites, and ops. Use contact for the FIH path and market-access for commercial holder / registration questions.
Do you publish freelancer or Pure Global rates here?
No. We do not invent competitor or freelancer rates. The only card we cite is the locked public LATAM Launch Subscription already on the hub.
Where do Mexico, Colombia, Brazil, and the LATAM hub sit?
Sibling RA-consultant intercepts: Regulatory Affairs Consultant Latin America; Mexico RA Consultant / COFEPRIS; Colombia RA Consultant / INVIMA; Brazil RA Consultant / ANVISA.
Next step
If the query that brought you here was Dominican Republic RA consultant / regulatory affairs consultant medical device, convert to the operator path: contact bioaccess® · market-access · siblings Regulatory Affairs Consultant Latin America; Mexico RA Consultant / COFEPRIS; Colombia RA Consultant / INVIMA; Brazil RA Consultant / ANVISA. Related: trial IOR · holder / IOR hub.
Julio G. Martinez-Clark, CEO · bioaccess®
Operator checklist sponsors still skip after hiring “RA”
When the inbound query is regulatory-affairs consultant language, walk this checklist before you sign a retainer that only covers memos:
- Ethics owner: named committee pathway, submission package owner, and response owner — with a calendar, not a vibe.
- Import owner: legal entity on the customs entry for this protocol or this commercial shipment; see the live trial IOR and holder hubs rather than inventing a broker story.
- Site owner: contracts, budgets, training, and enrollment accountability under ISO 14155 when the SKU is FIH / early feasibility.
- Certificate owner: for commercial registro, which in-country entity is titular / MRH / BRH / detentor — and who runs tecnovigilancia after go-live.
- Inspection owner: TMF/ISF discipline, monitoring, and CAPA. A classification PDF does not answer an inspector.
- Country-select owner: apply the Colombia public line before anyone sells you a new INVIMA FIH from an RA search; keep Mexico, Brazil, Panama, Chile, and El Salvador on the recommended FIH conversation where the live hubs support it.
- Commercial card owner: if the SKU is already-cleared devices, use the locked public LATAM Launch Subscription on market-access — USD 7,500/year all-in for the first device family — and do not invent freelancer comparables on this page.
- Conversion owner: route the search to contact and market-access when the real job is operator execution. Always bioaccess®.
bioaccess® is a DBA of IMH ASSETS CORP. Julio G. Martinez-Clark, Co-Founder and CEO. The founder podcast is Global Trial Accelerators™. This intercept is public content only. It is not leftover-site hospital FIH copy, not insurance underwriting, and not a Magical BTK page. Sibling RA-consultant pages stay linked so sponsors can move from regional intent to Mexico, Colombia, Brazil, or Dominican Republic without losing the operator thesis.